Jim Weiss, founder and chairman of Real Chemistry, and the 2025 HBA Honorable Mentor, discusses the foundation and journey ...

Results from the Phase III TEMPLE trial show that patients administered Qulipta (atogepant) experienced significantly fewer ...

Johnson & Johnson submitted a supplemental Biologics License Application to expand Stelara’s use to children aged two years ...

The key to improving SFE in 2025 lies in fundamentally reorienting measurement from representative activities to the value ...

Insights on ways pharmacy benefit managers can tap earned media to enhance their reputation—and demonstrate value through ...

The companies are working together to make it easier for companies to offer health plans that include these medications.

A study by GNC suggests that GLP-1s users are risking malnourishment and muscle loss. GNC announced the results of a study ...

Andembry is the first prophylactic therapy for hereditary angioedema to target factor XIIa, inhibiting the top of the ...